Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase NA 4Phase 1 3Phase 4 2Phase 2/3 2Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Conditions

Neoplasms 2012Carcinoma, Non-Small-Cell Lung 1228Breast Neoplasms 1215Leukemia, Myeloid, Acute 967Neoplasm Metastasis 902Melanoma 778Colorectal Neoplasms 752Multiple Myeloma 725Lymphoma 725Ovarian Neoplasms 675Pancreatic Neoplasms 665Lymphoma, Non-Hodgkin 659Prostatic Neoplasms 657Recurrence 637Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Lung Neoplasms 560Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 486Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 419Brain Neoplasms 415Squamous Cell Carcinoma of Head and Neck 389Stomach Neoplasms 387Carcinoma, Renal Cell 385Myelodysplastic Syndromes 382Carcinoma, Hepatocellular 368Advanced Solid Tumors 357Lymphoma, Mantle-Cell 345Glioma 343

Interventions

ublituximab 1Rituximab 1LFB-R603 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Myelitis, Transverse × Clear all
NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed
6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

NCT03138421 2019-01-25

Central Pain Study for ABX-1431

Abide Therapeutics

Phase 1 Completed
9 enrolled

Multiple Sclerosis, Myelitis, Transverse, Neuromyelitis Optica

NCT00501748 2011-09-27

Safety and Tolerability of Rituximab in Neuromyelitis Optica

University of California, San Francisco

Phase 1 Completed
20 enrolled

Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡